Literature DB >> 7827397

Do calcium channel blockers have renal protective effects?

G P Reams1.   

Abstract

Calcium channel blockers are used in the treatment of hypertension because of their ability to decrease peripheral vascular resistance. Recent research has suggested that these drugs also preserve or improve renal function in patients with essential hypertensive renal disease or diabetic renal disease, and in renal transplant recipients with or without cyclosporin therapy. In general, studies in animal models of hypertension and in hypertensive humans have demonstrated reduction in renal vascular resistance, and preservation or enhancement of renal plasma flow and glomerular filtration rate. In addition, calcium channel blockers appear to have a positive effect on renal addition, calcium channel blockers appear to have a positive effect on renal haemodynamic function in the setting of diabetes mellitus; prospective trials have also demonstrated reductions in urinary protein excretion in these patients. Current evidence suggests that calcium channel blockers are well-suited for the treatment of patients with hypertensive disease even in the presence of renal impairment, a clinical scenario common in the elderly population.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827397     DOI: 10.2165/00002512-199405040-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  205 in total

1.  The relation of vascular disease to the hypertensive state; the adequacy of the renal biopsy as determined from a study of 500 patients.

Authors:  B CASTLEMAN; R H SMITHWICK
Journal:  N Engl J Med       Date:  1948-11-11       Impact factor: 91.245

2.  Influence of nicardipine on blood pressure, renal function and plasma aldosterone in normotensive volunteers.

Authors:  B A van Schaik; R J Hene; G G Geyskes
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

3.  Blood pressure and renal function.

Authors:  S Ljungman; M Aurell; M Hartford; J Wikstrand; L Wilhelmsen; G Berglund
Journal:  Acta Med Scand       Date:  1980

4.  Antagonist capacities of nifedipine, captopril, phenoxybenzamine, prostacyclin and indomethacin on cyclosporin A induced impairment of rat renal function.

Authors:  H Dieperink; P P Leyssac; H Starklint; K A Jørgensen; E Kemp
Journal:  Eur J Clin Invest       Date:  1986-12       Impact factor: 4.686

5.  Regulation of sodium excretion in human hypertension: long-term effects of calcium antagonist and angiotensin converting enzyme inhibitor.

Authors:  P Coruzzi; L Musiari; G L Mossini; A Novarini
Journal:  J Cardiovasc Pharmacol       Date:  1993-06       Impact factor: 3.105

6.  Renal effects of a nonhypotensive i.v. dose of felodipine.

Authors:  P Larochelle; J R Cusson; P du Souich; G Thibault; B Edgar
Journal:  J Clin Pharmacol       Date:  1993-08       Impact factor: 3.126

7.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

8.  Calcium channel blockade with nitrendipine. Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans.

Authors:  F C Luft; G R Aronoff; R S Sloan; N S Fineberg; M H Weinberger
Journal:  Hypertension       Date:  1985 May-Jun       Impact factor: 10.190

9.  Control of glomerular hypertension by insulin administration in diabetic rats.

Authors:  J W Scholey; T W Meyer
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

10.  Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.